Business
Marina Biotech Appoints Robert Moscato to Chief Executive Officer
Marina Biotech Appoints Robert Moscato to Chief Executive Officer.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\nCity of Industry, CA, June 20, 2018 (GLOBE NEWSWIRE) -- Marina Biotech, Inc. (OTCQB: MRNA), a commercial stage pharmaceutical company focused on the development and commercialization of innovative therapeutics for hypertension, arthritis, pain and oncology, today announced that its Board of Directors has appointed Robert C. Moscato, Jr. to serve as Chief Executive Officer of the Company.\n Mr. Moscato served as the President and Chief Operating Officer of Cerecor, Inc. (NASDAQ: CERC) from November 2017 until March 2018, and he served on the Board of Directors of Cerecor Inc. from November 2017 until May 2018. Mr. Moscato also co-founded Zylera Pharmaceuticals, LLC and served as the CEO for over six years until it was acquired by Cerecor, Inc. in November 2017. Prior to that, Mr. Moscato served as Chief Operating Officer of Deston Therapeutics LLC. “Marina is at a very exciting inflection point,” Mr. Moscato said. “The company is building a commercial platform and infrastructure; and launching its first commercial product – PRESTALIA. We will focus on improving patient’s lives and growing the company both organically and inorganically. I want to express gratitude to the Board for this opportunity and look forward to working collaboratively to grow the Company, expand the portfolio and increase shareholder value.” Mr. Moscato is a serial pharmaceutical entrepreneur who has amassed his knowledge during more than 20 years in the pharmaceutical industry, including c-suite leadership and commercial roles. He has successfully built companies from the ground to an integrated organization. Mr. Moscato initially built his career in commercial roles of increasing responsibility with GlaxoSmithKline, where he was a member of the brand team that led the launch of Wellbutrin XL – one of the fastest launches in pharmaceutical history. Mr. Moscato earned an A.S. degree in Food and Nutrition from SUNY Farmingdale, a B.S. in Healthcare Management from St. Francis College and an M.B.A. from Iona College. In connection with the appointment of Mr. Moscato as Chief Executive Officer, Vuong Trieu, Ph.D., the Interim Chief Executive Officer of the Company, resigned from such position, and also from his position as Executive Chairman of the Company, effective immediately. “We would like to thank Dr. Trie...